Patents and the development on polymer based nanomaterial (PAMAM dendrimer) for biomedical applications

Recent Patents on Biomedical Engineering

Volumn 5, Issue 2, 2012, Pages 159-174

  Rajasekhar, Damaramadugu ^a,b   Liao, Pao Chi ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Biomedical applications; PAMAM dendrimer compositions; PAMAM dendrimer conjugations; PAMAM dendrimers; Patents

Indexed keywords

BIOMEDICAL ENGINEERING; BIOPHYSICS; DENDRIMERS; MEDICAL APPLICATIONS; MOLECULAR BIOLOGY; PATENTS AND INVENTIONS;

BIOMEDICAL APPLICATIONS; PAMAM DENDRIMER; PATENTS; PHOSPHOPEPTIDE ENRICHMENT; POLYAMIDOAMINE DENDRIMERS; POLYMER BASED; PROTEOMICS;

FUNCTIONAL POLYMERS;

EID: 84864545518     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764711205020159     Document Type: Review

References (188)

1. Buhleiver E, Wehner W, Vogtle F. Cascade, Non-skid-chain-like synthesis of molecular cavity topologies. Synthesis 1978; 2: 155-8.
2. stSPSJ International Polymer Conference, Society of polymer Science Japan, Kyoto. 1984; p65.
3. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: starburst Dendritic Macromolecules. Polym J 1985; 17: 117-32.
4. Tomalia DA, Dewald JR. Dense star polymers having core, core branches, terminal groups. US4507466, 1985.
5. Tomalia DA, Dewald JR. Dense star polymers. US4558120, 1985.
6. Tomalia DA, Dewald JR. Dense star polymers and dendrimer. US4568737, 1986.
7. Tomalia DA, Dewald JR. Dense star polymers having two dimensional molecular diameters. US4587329, 1986.
8. Tomalia DA, Dewald JR. Hydrolytically-stable dense star polyamine. US4631337, 1986.
9. Tomalia DA, Kirchhoff P. Rod-shaped dendrimer. US4694064, 1987.
10. Tomalia DA, Wilson L. Dense star polymers for calibrating/ characterizing sub-microns apertures. US4713975, 1987.
11. Tomalia DA. Bridged dense star polymers. US4737550, 1988.
12. Tomalia DA, Killat G. Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities. US4871779, 1989.
13. Tomalia DA, Stahlbush J. US4857599, 1989.
14. Tomalia DA, Naylor AM, Goddard WA. Molecular-level control of Size, Shape, Surface-Chemistry, Topology, and Flexibility flow Atoms to Macroscopic Matter. III. Angew Chem Int Ed Engl 1990; 29: 138-75.
15. Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Delivery Rev 2010; 62: 560-75.
16. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl 2009; 48: 872-97.
17. Zhao LB, Wu Q, Cheng Y, Zhang J, Wu J, Xu T. High-Throughput Screening of Dendrimer-Binding Drugs. Am Chem Soc 2010; 132: 13182-4.
18. Kannan RM, Menjoge AR, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discovery Today 2010; 15: 171-85.
19. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009; 71: 445-62.
20. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine 2008; 3: 679-702.
21. Svenson S, Tomalia DA. Dendrimers in biomedical applicationsreflections on the field. Adv Drug Delivery Rev 2005; 57: 2106-29.
22. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Delivery Rev 2005; 57: 2147-62.
23. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Controlled Release 2004; 95: 447-453.
24. Nijlah M, Freeman S, Attwood D, D'Emanuele A. In Vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 2007; 336: 183-90.
25. Jain NK, Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol 2008; 4: 1035-52.
26. Takade RK, Kumar PV, Jain NK. Dendrimers in Oncology: An Expanding Horizon. Chem Rev 2009; 109: 49-87.
27. Gupta U, Agashe HB, Asthana A, Jain NK. Dendrimers: Novel polymeric Nanoarchitectures for solubility Enhancement. Biomacromolecules 2006; 7: 649-58.
28. Pavan GM, Mintzer MA, Simanek EE, Merkel OM, Kissel T, Danani A. Computational Insights into the interactions between DNA and SiRNA with "Rigid" and "Flexible" Triazine Dendrimers. Biomacromolecules 2010; 11: 721-30.
29. Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer Chemistry. Prog Polym Sci 2005; 30: 294-324.
30. Tomalia DA. Dendrons/dendrimers: quantized, nano-element like building blocks for soft-soft and soft-hard nano compound synthesis. Soft Matter 2010; 6: 456-474.
31. Lee CC, Mackay JA, Frechet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005; 23: 1517-26.
32. Lee CC, Gillies ER. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci 2006; 103: 16649-54.
33. Gillies ER, Dy E, Frechet JMJ, Szoka FC. Bivological Evaluation of polyester Dendrimer: poly (ethyleneoxide) "Bow-Tie" Hybrids with Tunable molecular weight and Architecture. Mol Pharmaceutics 2005; 2: 129-38.
34. Gillies ER, Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today 2005; 10: 35-43.
35. Fréchet JMJ, Hawker CJ. Synthesis and Properties of Threedimensional dendritic Macromolecules: Dendrimers and hyperbranched polymers. Comprehensive Polymer Science 1996; S2: 71-132.
36. Morgan MT, Carnahan MA, Finkelstein S, Prata CAH, Degoricija L, Lee SJ, et al. Dendritic supramolecular assemblies for drug delivery. Chem Commun 2005; 34: 4309-11.
37. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, et al. Dendrimer-Encapsulated camptothecins: Increased solubility, Cellular Uptake, and Cellular Retention Affords Enhanced Anti-Cancer Activity in vitro. Cancer Res 2006; 66: 11913-21.
38. Smith PES, Brender JR, Durr UH, Xu J, Mullen DG, Banaszak Holl MM, Ramamoorthy A. Solid-State NMR Reveals the Hydrophobic-Core Location of poly (amidoamine) Dendrimers in Biomembranes. J Am Chem Soc 2010; 132: 8087-97.
39. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM. The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery plat form. Chem Biol 2007; 14: 107-15.
40. Hong S, Rattan R, Majoros IJ, Mullen DG, Peters JL, Shi X et al. The Role of Ganglioside GM1 in cellular internalization mechanisms of poly (amidoamine) dendrimers. Bioconjugate Chem 2009; 20: 1503-13.
41. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G et al. Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and ST1 prevention. Mol Pharmaceutics 2005; 2: 312-8.
42. Rupp R, Rosenthal SL, Stanberry LR. Vivagel (SPL 7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Pharm 2007; 2: 561-6.
43. ®CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clin Biochem 2004; 37: 679-83.
44. Yamano S, Dai J, Moursi AM. Comparison of transfection efficiency of nonviral gene transfer reagents. Mol Biotechnol 2010; 46: 287-300.
45. sted. New York: Wiley & Sons 2001.
46. Tomalia DA, Brothers HM II, Piehler LT, Durst HD, Swanson DR. Partial Shell-filled core-shell tecto(dendrimers): A strategy to sur face differentiated nano-clefts and cusps. Proc NatAcad Sci 2002; 99: 5081-7.
47. Frechet JMJ. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. Science 1994; 263: 1710-5.
48. Svenson S, Tomalia DA. Dendrimers in biomedical applications and reflections on the field. Adv Drug Deliv Rev 2005; 57: 2106-29.
49. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001; 6: 427-436.
50. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexatesensitive and resistant cell lines. Bioconjg Chem 2006; 17: 275-83.
51. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 2005; 16: 330-7.
52. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Preparation, cellular transport, and activity of polyamidoaminebased dendritic nanodevices with a high drug payload. Biomaterials 2006; 27: 660-9.
53. Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA, et al. Comparison of dendrimer based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 2003; 50: 758-66.
54. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett 2006; 6: 1459-63.
55. Tomalia DA, Esfand R. Dendrons, dendrimers and dendrigrafts. Chem Ind 1997; 11: 416-20.
56. Hecht S, Frechet JMJ. Dendritic encapsulation of function: applying nature's site isolation principle from biomimetics to materials science. Angew Chem Int Ed Engl 2001; 40: 74-91.
57. Jiang DL, Aida T. A dendritic iron porphyrin as a novel haemoprotein mimic: effects of the dendrimer cage on dioxygen-binding activity. Chem Commun 1996; 1523-4.
58. Dandiker PJ, Diederich F, Zingg A, Gisselbrecht J-P, Gross M, Louati A, et al. Dendrimers with porphyrin cores: symmetric models for globular heme proteins. Helv Chim Acta 1997; 80: 1773-1801.
59. Weyermann P, Gisselbrecht J-P, Boudon C, Diederich F, Gross M. Dendritic iron porphyrins with tetheredaxial ligands: new model compounds for cytochromes. Angew Chem Int Ed Engl 1999; 38: 3214-9.
60. Singh P, Moll F III, Lin SH, Ferzli C, Yu KS, Koshi RK, et al. Starburst dendrimers: enhanced performance and flexibility for immunoassays. Clin Chem 1994; 40: 1845-9.
61. Singh P, Moll F III, Lin SH, Ferzli C. Starburst dendrimers: a novel matrix for multifunctional reagents in immunoassays. Clin Chem 1996; 42: 1567-9.
62. Singh P. Terminal groups in starburst dendrimers: activation and reactions with proteins. Bioconjugate Chem 1998; 9: 54-63.
63. nded. Florida: CRC Press 2005.
64. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evolution of polyamidoamine (PAMAM) starburst dendrimers. J Biomed mater Res 1996; 30: 53-65.
65. Balogh L, Tomalia DA, Hangnaver GL. A revolution of nanoscale proportions. Chem Inn 2000; 30: 19-26.
66. Tomalia DA, Uppuluri S, Swanson DR, Brothers II HM, Piehler LT, Li J. Dendritic macromolecules: a fourth major class of polymer architecture-new properties driven by architecture. In Materials Research Society Symposium Proceedings. 1999; 543: 289-96.
67. Duncan R. Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway. Pharm Sci Technol Today 1999; 2: 441-9.
68. Duncan R, Seymour LW, O'Hare KB, Flanagan PA, Wedge S, Hume IC. Preclinical evaluation of polymer-bound doxorubicin. J Control Release 1992; 19: 331-46.
69. 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000; 65: 133-48.
70. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688-701.
71. Duncan R, Kopecek J. soluble synthetic polymers as potential drug carriers. Adv Polym Sci 1984; 57: 51-101.
72. Seymour LW, Duncan R, Strohalm J, Kopecek J. Effect of molecular weight (MW) of N-(2-hydroxypropyl)methaacrylamide copolymers on body distribution and rate of excretion after subcutaneous Intraperitoneal and intravenous administration to rats. J Biomed Mater Res 1987; 21: 1341-58.
73. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193-210.
74. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J Control Release 1992; 19: 315-24.
75. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K. Influence of molecular weight on passive tumor accumulation of a soluble macromoleculat drug carrier. Eur J Cancer 1995; 31A: 766-70.
76. Kopecek J, Duncan R. Targetable polymeric prodrugs. J Control Release 1987; 6: 3136-41.
77. Sprincl L, Exner J, Sterba O, Kopecek J. New types of synthetic infusion solutions: Elimination and retention of poly[N-(2-hydroxypropyl)methacrylamide] in a test organism. J Biomed Mater Res 1976; 10: 953-63.
78. Kopecek J. Soluble polymers in medicine, in Systemic Aspects of Biocompatibility. Ed Williams DF. Florida: CRC Press 1981.
79. Kopecek J, Rejmanova P, Duncan R, Lloyd JB. Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide Copolymers. Ann New York Acad Sci 1985; 446: 93-104.
80. Tomalia DA, Uppuluri S, Swanson DR, Brothers HM. Core-shell Tectodendrimers. US6635720, 2003.
81. Kurtoglu YE, Mishra MK, Kannan S, Kannan RM. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm 2010; 384: 189-94.
82. Liu M, Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci Tech Today 1999; 2: 393-401.
83. Hawker CJ, Frechet JMJ. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 1990; 112: 7638-47.
84. Haensler J, Szoka FC. Polyamidoamine cascade polymers mediate efficient-transfection of cells in culture. Bioconjugate Chem 1993; 4: 372-79.
85. Majoros IJ, Thomas TP, Mehta CB, Baker JR. Poly (amidoamine) Dendrimer-Based Multifunctional Engineered Nanodevice for Cancer Therapy. J Med Chem 2005; 48: 5892-99.
86. Labieniec M, Watala C. PAMAM dendrimers-diverse biomedical applications. Facts and unresolved questions. Curr Eur J Biol 2009; 4: 434-51.
87. Gillies ER, Dy E, Frechet JM, Szoka FC. Biological evalution of polyester dendrimer: poly(ethylene oxide) 'bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm 2005; 2: 129-38.
88. Nigavekar SS, Sung LY, Llanes M, El-Jawahari A, Lawrence TS, Becker CW, et al. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004; 21: 476-83.
89. Zhang ZY, Smith BD. High-generation polycationic dendrimers are unusually effective at disrupting anionic vesicles: membrane bending model. Bioconjugate Chem 2000; 11: 805-14.
90. Karoonuthasiri N, Titiyevskiy K, Thomas JL. Destabilization of fatty acid-containing liposomes by polyamidoamine dendrimers. Colloid Surf 2003; B27: 356-75.
91. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv drug Del Rev 2008; 60: 1037-55.
92. Seib FP, Jones AT, Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 malanoma cells. J Control Release 2007; 117: 291-300.
93. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, et al. Interaction of poly (amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjugate Chem 2004; 15: 774-82.
94. Fuchs S, Kapp T, Otto H, Schoneberg T, Franke P, Gust R, et al. A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization. Chem Eur J 2004; 10: 1167-92.
95. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-22.
96. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: starburst dendritic macromolecules. polym J 1985; 17: 117-32.
97. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003; 252: 263-6.
98. Jain NK, Nahar M. PEGylated Nanocarriers for systemic Delivery. Methods Mol Biol 2010; 624: 221-34.
99. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Delivery Rev 2005; 57: 2215-37.
100. Zhang YQ, Sun YH, Xu X, Zhang X, Zhu H, Huang L, et al. Synthesis, biodistribution, and micro single photon Emission Computed Tomography (SPECT) Imaging study of Technitium-99m labeled PEGylated dendrimer poly (amidoamine) (PAMAM)-Folic acid conjugates. J Med Chem 2010; 53: 3262-72.
101. Roy R, Baek MG. Glycodendrimers: novel glycotype isosters unmasking sugar coding. case study with T-antigen markers from breast cancer MUC1 glycoprotein. J Biotechnol 2002; 90: 291-309.
102. Zhang Y, Sun Y, Xu X, Zhu H, Huang L, Zhang X. Radiosynthesis and micro-SPECT imaging of 99mTc-dendrimer poly (amido)-amine folic acid conjugate. Bioorg Med Chem Lett 2010; 20: 927-31.
103. Zhuo RX, Du B, Lu ZR. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J Controlled Release 1999; 57: 249-57.
104. Lee H, Baker JR, Larson RG. Molecular dynamics studies of the size, shape, and internal structure of 0% and 90% acetylated fifthgeneration poly amidoamine dendrimers in water and methanol. J Phys Chem B 2006; 110: 4014-9.
105. Majoros IK, Keszler B, Woehler S, Bull T, Baker JR. Acetylation of poly (amidoamine) dendrimers macromolecules. 2003; 36: 5526-9.
106. Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL. Cytotoxicity of poly propylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 2007; 8: 3853-59.
107. Patil ML, Zhang M, Betigeri S, Taratula O, He H, Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjugate Chem 2008; 19: 1396-1403.
108. Zhao LB, Cheng YY, Hu JJ, Wu QL, Xu TW. Host-Guest Chemistry of dendrimer-drug complexes. 3. Competitive binding of multiple drugs by a single dendrimer for combination therapy. J Phys Chem B 2009; 113: 14172-79.
109. Fang M, Cheng Y, Zhang J, Wu Q, Hu J, Zhao L. New insights into interactions between dendrimers and surfactants. 4. Fastexchange/ slow-exchange transitions in the structure of dendrimersurfactant aggregates. J Phys Chem B 2010; 114: 6048-55.
110. Hu J, Fang M, Cheng Y, Zhang J, Wu Q, Xu T. Host-Guest Chemistry of dendrimer-drug complexes. 4. An in-depth look into the binding/encapsulation of guanosine monophosphate by dendrimers. J Phys Chem B 2010; 114: 7148-57.
111. Yang K, Cheng Y, Feng X, Zhang J, Wu Q, Xu T. Insights into the interactions between dendrimers and multiple surfactants: 5. Formation of miscellaneous mixed micelles revealed by a combination of 1H NMR, diffusion, and NOE Analysis. J Phys Chem B 2010; 114: 7265-73.
112. Wu QL, Cheng YY, Hu JJ, Zhao LB, Xu TW. Insights into the Interactions between dendrimers and bioactive surfactants: 3. Sizedependent and hydrophobic property-dependent encapsulation of bile salts. J Phys Chem B 2009: 113: 12934-43.
113. Hu J, Cheng Y, Wu Q, Zhao L, Xu T. Host-Guest Chemistry of dendrimer-drug complexes. 2. Effects of molecular properties of guests and surface functionalities of dendrimers. J Phys Chem B 2009; 113: 10650-9.
114. Hu JJ, Cheng YY, Ma YR, Wu QL, Xu TW. Host-Guest Chemistry and Physicochemical properties of the dendrimer-mycophenolic acid complex. J Phys Chem B 2009: 113: 64-74.
115. Cheng YY, Wu QL, Li YW, Hu JJ, Xu TW. New insights into the interactions between dendrimers and surfactants: 2. Design of new drug formulations based on dendrimer-surfactant aggregates. J Phys Chem B 2009; 113: 8339-46.
116. Cheng YY, Wu QL, Li YW, Xu TW. External electrostatic interaction versus Internal encapsulation between cationic dendrimers and negatively charged drugs: Which contributes more to solubility enhancement of the drugs?. J Phys Chem B 2008: 112: 8884-90.
117. Cheng YY, Li YW, Wu QL, Xu TW. New Insights into the interactions between dendrimers and surfactants by two dimensional NOE NMR spectroscopy. J Phys Chem B 2008: 112: 12674-80.
118. Feng X, Cheng Y, Yang K, Zhang J, Wu Q, Xu T. Host-Guest Chemistry of dendrimer-drug complexes. 5. Insights into the design of formulations for noninvasive delivery of heparin revealed by isothermal titration calorimetry and NMR Studies. J Phys Chem B 2010; 114: 11017-26.
119. Yang K, Weng L, Cheng Y, Zhang H, Zhang J, Wu Q. Host-Guest Chemistry of dendrimer-drug complexes. 6. Fully acetylated dendrimers as biocompatible drug vehicles using dexamethasone 21-phosphate as a model drug. J Phys Chem B 2011; 115: 2185-95.
120. Choi YJ, Kang SJ, Kim YJ, Lim Y, Chung HW. Comparative studies on the genotoxicity and cytotoxicity of polymeric gene carriers polyethylenimine (PEI) and polyamidoamine (PAMAM) dendrimer in Jurkat T-cells. Drug and Chemical Toxicology 2010; 33: 357-66.
121. Wang W, Xiong W, Wan J, Sun X, Xu H, Yang X. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 2009; 20: 105103-9.
122. Kim Y, Klutz AM, Jacobson KA. Systematic Investigation of Polyamidoamine dendrimers surface-modified with Poly (ethylene glycol) for drug delivery applications: Synthesis, Characterization, and Evaluation of Cytotoxicity. Bioconjugate Chem 2008; 19: 1660-72.
123. Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H. Surface Acetylation of Polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjugate Chem 2007; 18: 2054-60.
124. Tsai YJ, Hu CC, Chu CC, Imae T. Intrinsically Fluorescent PAMAM dendrimer as Gene carrier and nanoprobe for nucleic acids delivery: Bioimaging and Transfection Study. Biomacromolecules 2011; 12: 4283-90.
125. Patil ML, Zhang M, Betigeri S, Taratula O, He H. Surface-Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery. Bioconjugate Chem 2008; 19: 1396-03.
126. Patri AK, Kukowska-Latallo JF, Baker JR. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005; 57: 2203-14.
127. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexatesentive and resistant celllines. Bioconjug Chem 2006; 17: 275-83.
128. Khandare JJ, Jayant S, Singh S, Chandna P, Wang Y, Vorsa N. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 2006; 17: 1464-72.
129. Kamal MA, Nasim FH, Aljafari AA. In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate. Mol Cell Biochem 1996; 159: 47-53.
130. Meldal, M, Tornoe, CW. Cu-catalyzed Azide-Alkyne cycloaddition. Chem Rev 2008; 108: 2915-2952.
131. van Dijk M, Rijkers DTS, Liskamp RMJ, van Nostrum CF, Hennink WE. Synthesis and applications of Biomedical and Pharmaceutical polymers via Click Chemistry Methodologies. Bioconjug Chem 2009; 20: 2001-16.
132. Sletten EM, Nakamura H, Jewett JC, Bertozzi CR. Difluorobenzocyclooctyne: Synthesis, reactivity, and stabilization by _-Cyclodextrin. J Am Chem Soc 2010; 132: 11799-11705.
133. Huang B, Desai A, Zong H, Tang S, Leroueil P, Baker JR. Copperfree click conjugation of methotrexate to a PAMAM dendrimer platform. Tetrahedron Letters 2011; 52: 1411-14.
134. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int J Pharm 2005; 302: 29-38.
135. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15: 1174-81.
136. Blood brain barrier. Available at:http://en.wikipedia.org/wiki
137. He H, Li Y, Jia X, Du J, Ying X, Lu W, et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011; 32: 478-87.
138. Mishra MK, Kotta K, Hali M, Wykes S, Gerad HC. PAMAM dendrimer-azithromycin conjugates nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 2011; 7: 935-44.
139. Jones PH, Baker EJ, Rowley EK, Perun TJ. Chemical modifications of erythromycin antibiotics. 3. Synthesis of 4" and 11 esters of erythromycin A and B. J Med Chem 1972; 15:631-4.
140. Tomlinson I A, Kruper WJ, Headstrand DM, Tomalia DA, Kaplan DA, Fazio MJ, Wilson LR, Cheng RC. Soluble, radially symmetrical dense star polymer conjugates-comprises a star polymer and a carried material such as a contrast agent, diagnostic agent, agricultural or pharmaceutical active agent, etc. US5338532, 1994.
141. Tomlinson I A, Kruper W J, Cheng RC, Headstrand DM, Wilson LR, Chung CW, Tomalia DA, Kaplan DA, Edwards DS, Fazio MJ. Dense star polymer conjugates-comprising at least one dendrimer in association with one or more carried materials such as a drug. US5527524, 1996.
142. Baker JR, Sternson LA, Repp D, Ladenheim D. Methods of treating autoimmune disorders and/or inflammatory disorders. US0268731, 2011.
143. Bosnjakovic A, Mishra MK, Ren W, Kutoglu YE, Shi T. Poly (amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine 2011; 7: 284-94.
144. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5: 2674-81.
145. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specifictumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006; 17: 1109-15.
146. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
147. Kobayashi H, English RS, English S, Yordanov AT, Milenic DE, Sowers AL, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004; 10: 7712-20.
148. Das A, Zhou Y, Ivanov AV, Carter RL, Harden TK, Jacobson KA. Enhanced potency of Nucleotide-Dendrimer conjugates as agonists of the P2Y14 receptor: Multivalent effect in G Protein-Coupled receptor recognition. Bioconjugate Chem 2009; 20: 1650-59.
149. Kecskes A, Tosh DK, Wei Q, Gao ZG, Jacobson KA. GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists. Bioconjugate Chem 2011; 22: 1115-27.
150. Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D. Peptide-Conjugated PAMAM Dendrimer as a Universal DNA Vaccine Platform to Target Antigen-Presenting Cells. Cancer Res 2011; 71: 7452-62.
151. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213.
152. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Delivery Rev 2009; 61: 850-62.
153. Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv drug Delivery Rev 2009; 61: 760-66.
154. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
155. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.
156. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug discovery 2009; 8: 129-38.
157. Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2: 305-15.
158. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009; 6: 659-68.
159. Davis ME, Zuckerman JE et al, Hang CJ. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
160. Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
161. Akinc A, Zumbuhl A. A combinational library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26: 561-9.
162. Love KT, Mahon KP. Lipid-like materials for low-dose, in vivo gene silencing Proc Natl Acad Sci U S A 2010; 107: 1864-9.
163. Liu J, Zhou J, Luo Y. SiRNA delivery systems based on neutral cross-linked dendrimers. Bioconjugate Chem. 2012; 23: 174-183.
164. Rodrigo AC, Rivilla I, et al: Efficient, non-toxic hybrid PPVPAMAM dendrimer as a Gene Carrier for Neuronal Cells. Biomacromolecules. 2011; 12: 1205-13.
165. Magnetic resonance imaging. Available at: http://en.wikipedia.org/wiki
166. Kobayashi H, Kawamoto S, Brechbiel MW, Bernardo M, Sato N, Waldmann TA, et al. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinium-labeled dendrimer nanoparticle. Neoplasia 2005; 7: 984-91.
167. Malik N, Duncan R, Tomalia DA, Esfand R. Dendritic-Antineoplastic Drug Delivery system. US 7005124, 2006.
168. Klemm PJ, Floyd III WC, Andolina CM, Frechet JMJ, Raymond KN. Conjugation to biocompatible dendrimers increases lanthanide T2 relaxivity of hydroxypyridinone complexes for Magnetic Resonance Imaging. Eur J Inorg Chem 2012; 12: 2108-14.
169. Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjugate Chem 2008; 19: 2446-55.
170. Chauhan AS, Diwan PV, Jain NK, Tomalia DA. Unexpected In Vivo Anti-Inflammatory Activity Observed for Simple, Surface Functionalized Poly(amidoamine) Dendrimers. Biomacromolecules 2009; 10: 1195-02.
171. Dai H, Navath RS, Balakrishnan B, Guru BR, Mishra MK. Intrinsic targeting of neuroinflammation by polyamidoamine dendrimers in a rabbit model of cerebral palsy. Future Medicine: Nanomedicine 2010; 5:1317-29.
172. Kannan RM, Iezzi R., Rajaguru B, Kannan S. Dendrimers for sustained release of compounds. US0034422, 2010.
173. Kannan RM, Kannan S, Romero R, Navath RS, Dai H, Menjoge AR. Dendrimer based nanodevices for Therapeutic and Imaging purposes. US0003155, 2012.
174. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, et al. Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model. Sci Transl Med 2012; 4: 130-46.
175. Nanomaterials offer hope for cerebral palsy. Available at: http://www.nature.com/news-1.10475
176. Baker JR, Huang B. Dendrimer Compositions and Methods of Synthesis. WO2011059609, 2011.
177. Hedstrand, DM, Tomalia DA. Small Cell Foams and Blends and a process for their preparation. US5387617, 1995.
178. Hedstrand DM, Tomalia DA. Small Cell Foams containing a modified dense Star polymer or Dendrimer as a Nucleating agent US5393797, 1995.
179. Hedstrand DM, Tomalia DA. Polymer Blend containing a modified dense polymer or Dendrimer and a Matrix polymer. US5393795, 1995.
180. Hedstrand DM, Helmer BJ, Tomalia DA. Structured Copolymers and their use as Absorbents, Gels and carriers of Metal Ions. US5560929, 1996.
181. Hedstrand DM, Tomalia DA, Yin R. Non-crosslinked, Polybranched Polymers. US5773527, 1998.
182. Tao WA, Wollscheid B, O'Brien R, Eng JK, Li XJ, Bodenmiller B, et al. Nature Methods 2005; 2: 591-8.
183. Gomez-Escudero, Azagarsamy MA, Theddu N, Vachet RW, Thayumanavan S. J Am Chem Soc 2008; 130: 11156-63.
184. Tao WA. Materials and methods for isolating phosphopeptides. US0087008, 2010.
185. Iliuk AB, Martin VA, Alicie BM, Geahlen RL, Tao WA. Mol Cell Proteomics 2010; 9: 2162-72.
186. Tao WA, Iliuk AB. Reagents and methods for phosphorylation/ dephosphorylation analysis. WO2011130416, 2011.
187. Iliuk A, Martinez JS, Hall MC, Tao WA. Phosphorylation based on multifunctionalized soluble nanopolymer. Anal Chem 2011; 83: 2767-2774.
188. Tomalia DA, Majoros IJ. Biocompatible Dendrimers. US7078461, 2006.